Product analyses were restricted to those genes which had more than 1 SNP.
Affymetrix gene expression profiles were evaluated using linear modeling and rank product analyses.
FDA gave ENDS manufacturers two years to conduct and submit product analyses, nonclinical, and clinical analyses to support an ENDS product's impact on the public health.
Based on quantitative product analyses, major oxidation pathways of methyl 3-hexenoate and of methyl hexanoate were identified.
Product analyses showed that triphenylphosphine oxide and mixtures of polymeric oxidized salts of aniline are major products along with unreacted starting material.
CH and MR performed metabolic product analyses and analyzed the results.
The resultant supernatants were kept at 4°C for further substrate and product analyses.
This was true for hexose, pentose and the degradation product analyses, and for EH.
The rank product analyses were separated according to clinical staging between groups (CSI-CSIM, CSII-CSIIM, CSIII-CSIIIM).
